蛋白酶体
药品
类有机物
癌症研究
胶质母细胞瘤
蛋白酶体抑制剂
替莫唑胺
医学
高含量筛选
生物标志物
硼替佐米
药理学
体内
抗癌药
药物发现
化学
组蛋白脱乙酰基酶
药物开发
个性化医疗
RNA干扰
藤黄蛋白C
作者
Gerhard Jungwirth,Adrian Paul,Amélie Wöllner,Rolf Warta,Junguo Cao,Valentina Fermi,Lena Jassowicz,Philip Dao Trong,Andreas von Deimling,Juergen Debus,Sandro Manuel Krieg,Andreas W. Unterberg,Amir Abdollahi,Christel C. Herold‐Mende
标识
DOI:10.1038/s41698-026-01552-5
摘要
Abstract Personalized drug screening aims to improve the survival of glioblastoma (GBM) patients by identifying effective patient-individual drugs. Therefore, we conducted an automated high-throughput drug screening (aHTS) on standardized patient-derived glioblastoma tumor organoids (TOs). Robot-assisted aHTS was performed on TOs from 11 GBM patients. TOs fully compacted after two days, and the size remained stable over 10 days. TOs proliferated over time, and immunofluorescence stainings (GFAP, Tenascin C) confirmed tissue-like architecture. Anti-glioma effects with the lowest drug concentrations were achieved for proteasome inhibitors (carfilzomib, bortezomib, ixazomib), and HDAC inhibitors (panobinostat, romidepsin). Plasma C max -based drug levels ( C max /IC 50 > 1) used as a surrogate were only achieved for the three proteasome inhibitors and the HDACi romidepsin. The impact of their drug targets PSMB5 and HDAC1/2 on the growth of GBM cells was successfully validated by RNAi experiments. We established an aHTS platform for GBM TOs, and identified proteasome and HDAC inhibitors as promising drugs for the treatment of GBMs.
科研通智能强力驱动
Strongly Powered by AbleSci AI